I-SPY clinical trial shows promise in breast cancer therapy
Feb 18, 2011
A new report on WNDU highlights the promise of a pre-surgery chemotherapy trial called I-SPY, which is being conducted at the University of California, San Diego, and other centers.
"It's not so much killing cells as changing them. So they then can't go on to duplicate and become worse, and worse, and worse," Dr. Anne Marie Wallace, a breast cancer surgeon at the Moores University of California-San Diego Cancer Center, told the news source. "What you do is shrink the tumor enough that 65 percent of the time, when you thought you were going to have to remove the breast, you can actually just do a lumpectomy."
I-SPY 1 trials started in 2003, while I-SPY 2 trials started in 2010 and is still recruiting participants.
The I-SPY trial is a "national study to identify biomarkers predictive of response to therapy throughout the treatment cycle for women with Stage 3 breast cancer," according to the National Cancer Institute.
The study's main goals are to find biomarkers, study MRI imaging patterns, and subsequently the relationship between the two.